SOURCE: The St John Group

November 07, 2005 12:44 ET

Solanova's Nexrutine® Recognized as One of America's Top Pain Relievers by Consumer Health Digest

SAN FRANCISCO, CA -- (MARKET WIRE) -- November 7, 2005 -- It all started when Bob Garrison, a licensed pharmacist and CEO of Next Pharmaceuticals, Inc. decided to create a natural pain reliever that would rival Vioxx, Celebrex, Bextra and even aspirin. His intention was to eliminate the cardiovascular threat associated with some of the drugs on the market and develop a cardio-protective anti-inflammatory solution. In addition, he vowed to create a formula that would not impede the protective activity in the stomach cells the way aspirin does, leaving users more vulnerable to ulcers. After years of research in humans he came up with Nexrutine®, a proprietary patent-pending extract of Phellodendron amurense, a medicinal plant used in Asia for more than 2,000 years. Enter Solanova, a leading "Heart Health" dietary supplement company based in Northern California that saw the potential and jumped on the opportunity to distribute the long-awaited remedy to people suffering from pain associated with inflammatory disease and physical activity.

Today, Next Pharmaceuticals and Solanova revealed that Solonova's Nexrutine®, was declared one of America's Top 10 Pain Relievers by Consumer Health Digest. The health experts at the publication reviewed over 75 natural pain relief products currently available. Their rigorous assessment included review of the following product attributes: safety; joint and muscle pain relief; anti-inflammatory action; and support for healthy joints and connective tissue. "We're very excited about the recognition that Consumer Health Digest has given Nexrutine®," said Garrison. "We have known that it is one of the best natural anti-inflammatory products on the market. This recognition is very validating and it helps get the word out to the people who need it."

According to Mark Andersen, VP of Marketing for Solanova, "We are very pleased to receive a safety rating of 5 out of 5 from Consumer Health Digest. But, frankly, we expected nothing less given the clinical data on Nexrutine® proving how safe and effective it is."

Nexrutine® extract is a unique anti-inflammatory in that it keeps platelets from sticking together and thereby decreases the risk of stroke. Its primary anti-inflammatory compound has also been shown to significantly lower cholesterol demonstrating that it is truly a heart-protective anti-inflammatory.

Solanova, "The Heart Health Company", is a nutritional supplement company with the singular objective of helping optimize health and well-being utilizing the resources of nature. Founded over ten years ago in Northern California, Solanova is backed by millions of dollars invested in research and manufacturing. For more information go to www.Solanova.com.

Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients such as Relora®, Nexrutine®, Seditol® and Citri-Z™ to food, beverage, and dietary supplement companies seeking differentiation and a marketing edge with their healthy living products. For more information log onto www.nextpharmaceuticals.com.

Contact Information

  • Contact:
    Connie St John
    415-454-2243